To comprehensively quantify immune cell heterogeneity and spatial organization of glioblastoma tissue after anti-EGFR ILs-dox treatment, glioblastoma samples were collected from three patients who were planned for resection of relapsed disease and received anti-EGFR ILs-dox 24 h before surgery. The gene discussed is EGFR; the disease is glioblastoma.